Trial Details 4 Total Sites

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors

This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.

phase

Phase 1/Phase 2

status

Recruiting

enrollment

42

score

31

start date

2021-12-31

last updated

2022-01-07

New York City, New York
facility
Memorial Sloan Kettering Cancer Center
1 facility
Recruiting
Cincinnati, Ohio
facility
Cincinnati Children's Hospital Medical Center
1 facility
Recruiting
Randwick, Australia
facility
Sydney Children's Hospital
1 facility
Recruiting
Milano, Italy
facility
Istituto Nazionale Tumori di Milano; S.C. Oncologia Pediatrica
1 facility
Recruiting